Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Zavegepant is a third generation, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by Pfizer, under a license from Bristol-Myers Squibb, for the prevention and treatment of chronic and episodic migraine. In March 2023, zavegepant nasal spray (ZAVZPRET™) received its first approval in the USA for the acute treatment of migraine with or without aura in adults. Clinical development of an oral formulation of zavegepant is currently underway. This article summarizes the milestones in the development of zavegepant leading to this first approval for the acute treatment of migraine with or without aura in adults.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209931 | PMC |
| http://dx.doi.org/10.1007/s40265-023-01885-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Do high-volume centers really save more lives? A call for scientific rigor and transparency. Response to Comment on: Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy.
Haematologica
September 2025
University Hospital Heidelberg, Heidelberg.
Not available.
View Article and Find Full Text PDFWild-type p53 overexpression in -mutated acute myeloid leukemia: potential implications for disease biology and therapy response.
Haematologica
September 2025
Division of Hematopathology, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, NY; Multiparametric In Situ Imaging (MISI) Laboratory, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York.
Not available.
View Article and Find Full Text PDFEarly cytokine and chemokine signals shape the anti-AML activity of bispecific engager-secreting T cells.
Haematologica
September 2025
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD,.
Immunotherapies, including cell therapies, are effective anti-cancer agents. However, cellular product persistence can be limiting with short functional duration of activity contributing to disease relapse. A variety of manufacturing protocols are used to generate therapeutic engineered T-cells; these differ in techniques used for T-cell isolation, activation, genetic modification, and other methodology.
View Article and Find Full Text PDFImmune intervention is dispensable for retinoic acid/arsenic therapy of murine acute promyelocytic leukemia.
Haematologica
September 2025
Université Paris-Cité, INSERM U1342, CNRS EMR8000, IRSL, Hôpital Saint-Louis, Paris, France; Collège de France, Chaire d'Oncologie Cellulaire et Moléculaire, PSL Research University, and INSERM U1050, CNRS UMR 7241, Paris, France; Service d'hématologie biologique, Hôpital Saint-Louis, AP/HP,
Not available.
View Article and Find Full Text PDFAntibiotic Therapy for Pyelonephritis in the Emergency Department.
Emerg Med Australas
October 2025
Emergency and Trauma Centre, The Alfred Hospital, Melbourne, Victoria, Australia.
Objectives: Acute pyelonephritis (APN) is a common diagnosis among patients presenting to the Emergency Department (ED). It is treated by empiric antibiotics within the ED. With a rise in antimicrobial resistance globally, it is unknown whether patients are being managed with empiric antibiotics that are appropriate for the causative organisms of APN.
View Article and Find Full Text PDF